KNSA Kiniksa Pharmaceuticals International, plc Insider Trading

CMO John F. Paolini nets ~$3.1M selling majority stake while simultaneously buying stock at lower price

Paolini, Kiniksa's Chief Medical Officer, executed a complex transaction pattern on the same day: a small opportunistic buy of lower-priced shares paired with substantial sales of holdings at current market levels—netting over $3 million in proceeds. This mixed activity doesn't fit the typical insider-conviction narrative; rather, it looks like disciplined portfolio rebalancing by someone with deep operational knowledge. The timing is notable: the stock is trading at its 52-week highs following a rapid recovery, yet Paolini is trimming his position while the company is profitable with accelerating revenue growth. His decision to sell near the peak while the fundamentals remain strong and the valuation appears stretched suggests a focus on risk management—not panic, but prudent profit-taking by a C-suite executive. The smaller buy component may reflect confidence in the company's long-term trajectory, even as he reduces near-term exposure.

KNSA Chairman & CEO Patel Sanj K sells entire 48,565-share position for $2,623,481.30 under 10b5-1 plan

Patel Sanj K, serving as Chairman and CEO of Kiniksa Pharmaceuticals, sold 48,565 shares on 2026-05-01 at $54.02 per share for a total value of $2,623,481.30, reducing his holdings to 0 shares. This represents a complete liquidation of his shareholding position. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than a discretionary decision made at the time of execution. A full exit by the chief executive merits investor attention given the officer's visibility into company prospects and the signal conveyed by complete divestiture of personal equity stakes.

KNSA CEO Patel sold 508,339 shares for $26,415,228.13 across 6 trades (Apr 28-30), exiting entire position

Sanj K Patel, Chairman & CEO of Kiniksa Pharmaceuticals, executed 6 separate sales totaling 508,339 shares for $26,415,228.13 between April 28-30, 2026, at prices ranging from $50.43 to $54.02 (blended average $51.96). This transaction completely liquidated his entire shareholding (from 508,339 shares to 0 shares post-transaction, a -100.0% change in his holdings). The filing is marked as part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary. Complete exit of a CEO's position warrants investor scrutiny regardless of the predetermined schedule, as it represents a material change in insider ownership stakes and potential signaling about confidence levels.

CFO Ragosa sold 36,722 shares for $1.7M under pre-arranged 10b5-1 plan

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, executed 2 separate sales totaling 36,722 shares for $1,686,157.82 on 2026-03-09 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings from 48,808 shares to 12,086 shares, a reduction of 75.2% of his pre-transaction position. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects a predetermined trading arrangement rather than a real-time market decision. Investors should note the substantial reduction in CFO stake but recognize that the timing and structure are governed by the plan agreement, not contemporaneous trading judgment.

CMO John F. Paolini sold 40,000 shares at $44.20–$45.92 for $1.8M; holds 61,324 post-sale as KNSA rallies.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, executed 3 separate sales totaling 40,000 shares for $1,792,939.72 at prices ranging from $44.20 to $45.92, reducing his holdings by 39.5%. The sale occurred near the stock's 52-week high of $47.77 and follows strong recent price momentum: KNSA rose 5.8% over 30 days and 15.3% over 90 days prior to this filing. Paolini's prior trades at KNSA show mixed timing outcomes—his 2 most recent sales (October 2025 and August 2025) were followed by strong 30-day and 90-day gains, whereas his 2024 sales preceded declines, yielding a 40% well-timed rate at this ticker. The company's fundamentals remain robust: $180.9M in latest quarterly revenue with 60.1% annual growth and positive net income of $18.4M, though the P/E of 59.09 reflects elevated valuation. The materiality of this sale lies in its scale (40K shares) and timing proximity to the stock's recent highs, warranting observation of whether this signals adjusted exposure or a discrete portfolio action.

CFO Ragosa sells 17,845 shares ($772.3K) in 2 transactions via scheduled 10b5-1 plan

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, executed 2 separate sales totaling 17,845 shares for $772,254.22 on 2026-02-09, reducing his holdings by 59.6% from 29,931 shares to 12,086 shares. This transaction is scheduled under a pre-arranged 10b5-1 trading plan, meaning it was not a discretionary decision but rather a pre-programmed execution at specified price points ($42.85 and $43.72 per share). Because the sale follows a structured plan rather than a real-time trading decision, it does not carry the typical signal-laden characteristics of discretionary insider selling. The material reduction in CFO stake warrants tracking of any subsequent filings or announcements to understand the underlying context driving the predetermined plan.

CFO Mark Ragosa sold 12.0K shares of KNSA at $41.89 on 2026-01-08, reducing holdings 38.6%; stock now $42.67, near 52-week high of $43.52.

Mark Ragosa, KNSA's Chief Financial Officer, sold 12,000 shares at $41.89, representing a 38.6% reduction in his shareholdings from 31.1K to 19.1K shares. The sale occurred near the stock's 52-week high of $43.52 (current price $42.67 is -2.0% below that peak). Over his same-ticker history at KNSA, Ragosa has executed 5 prior sales, with only 3 measurable 90-day outcomes showing mixed results: 0 of the 3 measured periods saw the stock decline post-sale (one showed +12.5%, another +16.3%, and a third +8.1%), indicating his prior KNSA sales were poorly timed from a downside-avoidance perspective. The company shows strong topline momentum with annual revenue growth of +56.6%, though it reported full-year net loss despite recent quarterly net income of $18.4M, creating a profile of growth combined with underlying profitability challenges.

KNSA COO Tessari sells 12,048 shares at $41.56; holding drops 42.0% to 16.7K; stock up 15.4% in 90 days.

Tessari Eben, Chief Operating Officer, sold 12,048 shares at $41.56, reducing his holdings by 42.0% from 28.7K to 16.7K shares. The stock has traded favorably in recent months, up 15.4% over the past 90 days and currently near its 52-week high at $41.47 (down only 2.9% from the peak of $42.71). At the same ticker over 5 prior trades, his prior sells have consistently generated positive 90-day returns (ranging from +12.4% to +14.1% on the two measured sales), indicating his recent sales at KNSA have not preceded declines. His cross-ticker track record shows 16 prior sells with a 0.00% well-timed rate, meaning he did not sell ahead of price drops. The company's fundamentals show strong recent growth—annual revenue is up 56.6% with latest-quarter revenue of $180.9M—though it remains unprofitable on a full-year basis. This sale occurs in a context of appreciating stock price and healthy corporate momentum, without evidence of poor timing on the insider's part.

CFO Mark Ragosa sold 42,841 shares of KNSA at $41.49 via 10b5-1 plan; post-sale holdings 31,086 shares

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, sold 42,841 shares valued at $1,777,473.09 on 2025-12-08 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings from 73,927 shares to 31,086 shares, a reduction of -58.0% from pre-transaction levels. Because this transaction was scheduled under a 10b5-1 plan rather than discretionary, it reflects a predetermined trading program established in advance and does not indicate timing-based investment decisions. Investors should note the magnitude of the reduction in the CFO's stake, though the planned nature of the sale limits inference about current market or company-specific conditions.

COO Tessari sells 12,470 shares (35.4% of holdings) at avg $41.24; stock now at $42.16

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, executed 2 separate sales totaling 12,470 shares for $514,224.10 on 2025-11-17 at an blended average price of $41.24—slightly below the current price of $42.16. The sale reduces his post-transaction holdings from 35,184 to 22,714 shares, a reduction of 35.4% of his pre-transaction position. Evaluating timing context: his cross-ticker track record shows an average 90-day return of +18.8% after prior sells with a 0.00% well-timed rate, indicating those sales have historically been poorly timed (stock rose after). His same-ticker history at KNSA across 5 prior sells shows mixed near-term outcomes (30-day range from -2.5% to +8.4%), though 90-day measurement outcomes are not yet available. The company is on strong growth trajectory (revenue +56.6% year-over-year) with recent profitability ($18.4M net income on $180.9M quarterly revenue), providing fundamental backdrop for recent stock appreciation (+8.1% in 30 days, +25.6% in 90 days, now at 52-week high of $42.16). This represents a substantial reduction in CEO equity ownership during an appreciated price environment.